Skip to main content

Anti-Rheumatic Rx

Malar,rash,SLE, Lupus

Low Dose IL-2 Therapy in SLE

Aug 17, 2022

A multicentre, proof-of-concept trial of suggests that low-dose IL-2 therapy may be effective in moderate-to-severe systemic lupus erythematosus (SLE). This is not surprising as IL-2 is needed to bolster insufficient regulatory T cell (Treg) activity, thought to be pivotal to the

Read Article
woman-1284353_640.jpg

Favorable Pregnancy Outcomes in Spondyloarthritis

Aug 16, 2022

Pregnancy often occurs in women with axial spondyloarthritis (axSpA), and a recent cohort study suggests outcomes are generally better than what had been reported in the literature.



Data was collected from axSpA patients from 4 registries who were pregnant. This included a total of

Read Article
JIA_0.jpg

JUNIPERA Study - Secukinumab in Juvenile PsA & ERA

Aug 16, 2022

JUNIPERA study evaluated secukinumab (SEC) in children with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) and was found to be safe and effective in patients with active ERA and JPsA who previous failed to respond to conventional therapy.

Read Article
gout.MTP1_.jpg

Black Adults Have a Higher Gout Risk

Aug 15, 2022

In a cross-sectional study of US adults, gout was more prevalent in black adults compared to white adults; possibly explained by sex-specific dietary differences and social determinants of health and clinical factors. 



Population data was derived from survey of 18,693 participants in

Read Article
Screen%20Shot%202020-03-27%20at%2010.15.17%20AM.png

Global Mortality Rates for PsA, SpA and Colitis

Aug 12, 2022

Global age-standardized mortality rate (ASMR) for 1000000 was for 0.13 for AS, 0.04 for PsA, 0.86 for CD and 0.76 for UC.



Using mortality data from the World Health Organisation (WHO), researchers showed that over time, while there has been no change in age-standardized mortality

Read Article
RheumNow Podcast square

Hit Parade Review (8.12.2022)

Aug 12, 2022

We've got a lot to discuss this week: psoriasis; fatigue; sleep; sural nerve biopsies; uveitis and SpA; diet and RA; tofacitinib and the ORAL surveillance study; what not to take with mycophenolate - and more. In what order should these items be discussed? This week the run down is based on

Read Article
Sleep.fatigue.doctor.jpg

Fatigue is Under-Appreciated in Psoriatic Arthritis

Aug 09, 2022

Patient-reported fatigue is high in patients with psoriatic arthritis (PsA) and often goes under-recognized by physicians. Fatigue importantly impacts physical functioning, work productivity, and health related quality of life (HRQoL).

Read Article
GCA,Black

Increased Mortality in Giant Cell Arteritis

Aug 09, 2022

A population-based study from Ontario, Canada suggests an increased mortality risk in patients with giant cell arteritis (GCA), according to a recent report in Arthritis Care & Research.



A health administrative data study looked at 22,677 GCA patients (≥50 years of age)

Read Article
URI.infection.COrona.jpg

More Bad Safety News for Xeljanz

MedPage Today
Aug 08, 2022

Another analysis of the mandatory postmarketing safety study for tofacitinib (Xeljanz) has confirmed what most observers expected: that rates of infection with the drug in rheumatoid arthritis are higher than with tumor necrosis factor (TNF) inhibitors.

Read Article
Study of 57 #RA pts. w/ ILD treated with abatacept. Lung progression in 46% before ABA. After median 27 mos of follow-up, ILD - 72% improved or stabilized - 23% worsened - 5% died. No significant change in FVC, DLCO ILD worse assoc w/ DAS28, FVC DLCO https://t.co/kLa61ZS8dt https://t.co/7XhqxcHuCt
Dr. John Cush @RheumNow( View Tweet )
Aug 08, 2022
doctor.study_.decision_0.jpg

JAK Inhibitors in Difficult Still’s Disease

Aug 05, 2022

A small retrospective study suggests that patients with difficult to treat adult-onset Still's disease (AOSD) or sytemic juvenile idiopathic arthritis (sJIA) may respond well to JAK inhibitor (JAKi) agents - presumable by blocking pro-inflammatory cytokines, notably IL-6 and IFN.



Read Article
RheumNow Podcast square

The Great Unknowns (8.5.2022)

Aug 05, 2022

Dr. Jack Cush reviews the news, FDA approvals, journal articles from the past week on RheumNow; plus viewer questions. This week great hopes for vitamin D, the great unknows of CSA and the great big mess that is the gout.




  1. 521 clinically suspect arthralgia (CSA) pts were

Read Article
Study of Erythrocyte MTX-polyglutamates (MTX-PG1-5) levels in Crohns patients shows that age, lower GFR and subcutaneous #MTX use all significantly increase RBC MTX-polyglutamate levels (all risk factors for MTX toxicity) https://t.co/469eMqbCBC https://t.co/8LoarfIyV4
Dr. John Cush @RheumNow( View Tweet )
Aug 04, 2022
ACR guidance

ACR Updated Guideline on Vaccinations for Rheumatic Patients

Aug 04, 2022

The ACR has posted a new ACR Clinical Practice Guideline Summary providing recommendations on the use of vaccinations for children and adults with rheumatic and musculoskeletal diseases (RMDs).



This guideline builds on past

Read Article
CV,risk,MI,heart,cardiac

Gout Flares Up Cardiac Risks

Aug 03, 2022

A large case-control study showed that gout patients who experienced a cardiovascular (CV) event were more likely to have had a recent (< 120 days) gout flare compared to those without CV events.



This study sought to investigate the temporal association between gout flares and

Read Article
RA erosions bone ACR

The Approach to Difficult to Treat Rheumatoid Arthritis

Aug 03, 2022

Tan and Buch have reviewed the approach to difficult to treat rheumatoid arthritis (D2T-RA), with a new EULAR definiation of D2T-RA to foster an approach rationale and concideration of treatment options.



D2T-RA is defined by failure of at least two different mechanism of action

Read Article
hip,fracture3

Supplemental Vitamin D Fails to Lower Fracture Risk

Aug 02, 2022

NEJM has published study results showing that vitamin D3 supplementation does not significantly lower fracture risk (vs. placebo) when used in generally healthy adults.

Read Article
knee,pain3,target

Krill Oil Effective in Knee Osteoarthritis

Aug 02, 2022

Krill oil supplements in knee osteoarthritis (OA) was shown to be superior to placebo in reducing knee pain, stiffness and function while increasing the omega-3 index. Krill oil, rich in anti-inflammatory long-chain (LC) omega-3 ( ω–3) PUFAs and astaxanthin, is thought to be safe and now

Read Article
DLE discoid lupus

Plasmacytoid Dendritic Cell Inhibitor in Cutaneous Lupus

Aug 01, 2022

Litifilimab, a humanized monoclonal antibody against BDCA2, targets the BDCA2 receptor on plasmacytoid dendritic cells. When administered to patients with cutaneous lupus erythematosus (CLE) was shown reducing disease activity in CLE patients.

Read Article
LBP.red_.jpg

Upadacitinib in non-radiographic Axial Spondyloarthritis

Aug 01, 2022

The janus kinase inhibitor, upadacitinib, has been shown to significantly improve the signs and symptoms of non-radiographic axial spondyloarthritis (nr-AxSpA), extending the efficacy of UPA beyond classic ankylosing spondylitis.

Read Article
RheumNow Podcast square

Social Media Questions (7.29.2022)

Jul 29, 2022

Dr. Jack Cush reviews the news, journal reports and rheumatologist cases from the past week on RheumNow.com. This podcast is brought to you by StillsNow.com - be sure to sign up for our monthly StillsNow email and Monthly StillsNow Podcast.




  1. Study of 63 Thalassemia pts (50

Read Article
Lungs ILD

Approach to ILD in Myositis Syndromes

Jul 28, 2022

Mehta et al have published a full read review of managing interstitial lung disease (ILD) in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.



They divide myositis-ILD into three main prognostic

Read Article
blood, level, numbers, data, calculation

Best Labs for Still’s Disease

Jul 27, 2022

There is no “test” (blood or other) that is solely diagnostic of Still’s disease, but labs can help make a diagnosis or manage disease, and affirm the safety of drugs in use. ​​​​​​​ 

Read Article
BSRBR mandates LFTs q3 mos if on MTX. 1011 RA pts during the pandemic had median of 5 blood tests & median interval of 57 days. 61% pts had 1 prolonged interval (99-150d) & 24% had multiple. Cytopenia & ^LFTs were not increased by interval length https://t.co/VqY4qIMvOS https://t.co/HcTcmFBuvq
Dr. John Cush @RheumNow( View Tweet )
Jul 27, 2022
210 consecutive #RA pts starting #MTX looked at effect of autoantibodies on drug response. DAS28-CRP low dz activity at 6 mos was significantly lower with SSA+ (56% v 76%, P=0.03) - which was more significant than CCP+ or RF+ https://t.co/DoEtldBXi4Figures https://t.co/yIECjLiEwl
Dr. John Cush @RheumNow( View Tweet )
Jul 27, 2022
×